Mechanism-based target identification and drug discovery in cancer research
JB Gibbs - Science, 2000 - science.org
Cancer as a disease in the human population is becoming a larger health problem, and the
medicines used as treatments have clear limitations. In the past 20 years, there has been a …
medicines used as treatments have clear limitations. In the past 20 years, there has been a …
Selective estrogen receptor modulators in reproductive medicine and biology
VL Baker, D Leitman, RB Jaffe - Obstetrical & gynecological …, 2000 - journals.lww.com
Estrogen replacement therapy has significant potential benefits for postmenopausal women,
such as improvement of menopausal symptoms and protection from osteoporosis, but it may …
such as improvement of menopausal symptoms and protection from osteoporosis, but it may …
Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
JMG Schafer, H Liu, DJ Bentrem, JW Zapf, VC Jordan - Cancer Research, 2000 - AACR
The active metabolite of tamoxifen, 4-hydroxytamoxifen (4-OHT), is used in the laboratory for
mechanistic studies of antiestrogen action. This compound binds to the estrogen receptor α …
mechanistic studies of antiestrogen action. This compound binds to the estrogen receptor α …
Progress in the prevention of breast cancer: concept to reality
VC Jordan - The Journal of steroid biochemistry and molecular …, 2000 - Elsevier
In 1936, Professor Antoine Lacassagne suggested that breast cancer could be prevented by
developing drugs to block estrogen action in the breast. Jensen discovered the physiologic …
developing drugs to block estrogen action in the breast. Jensen discovered the physiologic …
[引用][C] Editorial Board BW Stewart, MSc, PhD, FRACI RL Ward, MBBS, PhD, FRACP
L White, LA Wright - Cancer Forum, 2000